IN RE BIOLINERX LTD. SECURITIES LITIGATION

2:23-cv-00041

Class Action

July 16, 2024
Drugmaker BioLineRx Beats Investor Suit Over Cash Shortfall

Israeli biotech company BioLineRx has, for now, beaten a proposed class action over claims that it misled investors on its capital shortfall, which caused a major decline in its share price, with a New Jersey federal judge saying the plaintiffs have failed to plead any actionable misleading or false statements.
March 21, 2023
Glancy Prongay Drops Out Of Blood Drug Lead Counsel Race

Glancy Prongay & Murray withdrew its bid to serve as lead counsel in a proposed class action brought against an Israeli biotech company accused of misleading its investors, stating that after further review it does not think its client is the "most adequate plaintiff."
March 08, 2023
3 Firms Face Off For Lead Counsel Spot In Blood Drug Suit

It's a battle of law firm resumes as three firms vie for the lead counsel spot to represent investors in a securities class action against an Israeli biotech firm that is alleged to have misled its shareholders about a new blood therapy.
January 05, 2023
Investor Says Biotech Co. Hid Blood Treatment Funding Woes

Israeli biotechnology company BioLine misled the public and its shareholders about its financing shortfalls for a new blood therapy, then ultimately caused a 33% stock drop when it made moves to shore up funding for the product's commercial launch, according to a lawsuit filed Thursday.